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Metabolomics is a rapidly evolving discipline that involves the systematic study of endogenous small molecules that characterize
the metabolic pathways of biological systems. The study of metabolism at a global level has the potential to contribute significantly
to biomedical research, clinical medical practice, as well as drug discovery. In this paper, we present the most up-to-date metabolite
and metabolic pathway resources, and we summarize the statistical, and machine-learning tools used for the analysis of data from
clinical metabolomics. Through specific applications on cancer, diabetes, neurological and other diseases, we demonstrate how
these tools can facilitate diagnosis and identification of potential biomarkers for use within disease diagnosis. Additionally, we
discuss the increasing importance of the integration of metabolomics data in drug discovery. On a case-study based on the Human
Metabolome Database (HMDB) and the Chinese Natural Product Database (CNPD), we demonstrate the close relatedness of the
two data sets of compounds, and we further illustrate how structural similarity with human metabolites could assist in the design
of novel pharmaceuticals and the elucidation of the molecular mechanisms of medicinal plants.
1. Introduction
Metabolomics is a new technology that applies advanced
separation and detection methods to capture the collection
of small molecules that characterize metabolic pathways.
This rapidly developing discipline involves the study of the
total repertoire of small molecules present in the biological
samples, particularly urine, saliva, and blood plasma [1].
Metabolites are the byproducts of metabolism, which is itself
the process of converting food energy to mechanical energy
or heat. Experts believe there are at least 3,000 metabolites
that are essential for normal growth and development (pri-
marymetabolites) and thousandsmore unidentified (around
20,000, compared to an estimated 30,000 genes and 100,000
proteins) that are not essential for growth and development
(secondary metabolites) but could represent prognostic,
diagnostic, and surrogate markers for a disease state and
a deeper understanding of mechanisms of disease [2]. Of
particular interest to metabolomics researchers are small,
low-molecular weight compounds that serve as substrates
and products in various metabolic pathways [3].
Metabolomics, the study of metabolism at the global
level, has the potential to contribute significantly to biomedi-
cal research, and ultimately to clinical medical practice [4, 5].
It is a close counterpart to the genome, the transcriptome
and the proteome. Metabolomics, genomics, proteomics,
and other “-omics” grew out of the Human Genome Project,
a massive research eﬀort that began in the mid-1990s and
culminated in 2003 with a complete mapping of all the genes
in the human body. When discussing the clinical advantages
of metabolomics, scientists point to the “real-world” assess-
ment of patient physiology that the metabolome provides
since it can be regarded as the end-point of the “-omics”
cascade [6]. Other functional genomics technologies do
not necessarily predict drug eﬀects, toxicological response,
or disease states at the phenotype but merely indicate the
potential cause for phenotypical response. Metabolomics
can bridge this information gap since the identification
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and measurement of metabolite profile dynamics of host
changes provides the closest link to the various phenotypic
responses [7–9]. Thus it is clear that the global map-
ping of metabolic signatures pre- and postdrug treatment
is a promising approach to identify possible functional
relationships between medication and medical phenotype
[10–13].
At the center of metabolomics is the concept that an
individual’s metabolite state is a close representation of the
individuals overall health status. This metabolic state reflects
what has been encoded by the genome and modified by
environmental factors. In this paper, we demonstrate the
enormous potential of metabolomics in disease monitor-
ing and identification of prognostic, diagnostic, and drug
response markers (Figure 1 (i)–(iii)), as well as in drug
discovery and development in combination with systems
chemical biology and chemoinformatics (Figures 1(a)–1(c)).
2. Databases and Data Analysis Tools
Databases of metabolites and metabolic reactions oﬀer a
wealth of information regarding the interaction of small
molecules with biological systems, notably in relation with
their chemical reactivity. In Table 1, we summarize all
such metabolite and metabolic pathway resources which
contain hundreds of reactions, metabolites, and pathways
for several organisms and are designed to facilitate the
exploration of metabolism across many diﬀerent species.
For example, the BiGG database (http://bigg.ucsd.edu/) is
a metabolic reconstruction of human metabolism designed
for systems biology simulation and metabolic flux balance
modelling. It is a comprehensive literature-based genome-
scale metabolic reconstruction that accounts for the func-
tions of 1,496 ORFs, 2,004 proteins, 2,766 metabolites,
and 3,311 metabolic and transport reactions. MassBank
(http://www.massbank.jp/) is a mass spectral database of
experimentally acquired high resolution MS spectra of
metabolites. Maintained and supported by the JST-BIRD
project, it oﬀers various query methods for standard spectra
obtained from Keio University, RIKEN PSC, and other
Japanese research institutions. It is oﬃcially sanctioned
by the Mass Spectrometry Society of Japan. The database
has very detailed MS data and excellent spectral/structure
searching utilities. More than 13,000 spectra from 1900
diﬀerent compounds are available. The METLIN Metabolite
Database (http://metlin.scripps.edu/index.jp) is a repository
for mass spectral metabolite data. All metabolites are
neutral or free acids. It is a collaborative eﬀort between
the Siuzdak and Abagyan groups and Center for Mass
Spectrometry at The Scripps Research Institute. METLIN is
searchable by compound name, mass, formula, or structure.
It contains 15,000 structures, including more than 8000
di- and tripeptides. METLIN contains MS/MS, LC/MS and
FTMS data that can be searched by peak lists, mass range,
biological source or disease. Below we describe in more detail
three interconnected databases; the Human Metabolome
Database (http://www.hmdb.ca/), the Small Molecule Path-
way Database (http://www.smpdb.ca/) and the Toxin and
Toxin-Target Database (http://www.t3db.org/) (Figure 2).
2.1. Human Metabolome Database (HMDB). Focusing on
quantitative, analytic, or molecular scale information about
metabolites, the enzymes and transporters associated with
them, as well as disease related properties the HMDB rep-
resents the most complete bioinformatics and chemoinfor-
matics medical information database. It contains records for
thousands of endogenous metabolites identified by literature
surveys (PubMed, OMIM, OMMBID, text books), data
mining (KEGG, Metlin, BioCyc) or experimental analyses
performed on urine, blood, and cerebrospinal fluid samples.
The annotation eﬀort is aided by chemical parameter calcu-
lators and protein annotation tools originally developed for
DrugBank. The HMDB is fully searchable with many built-
in tools for viewing, sorting, and extracting metabolites,
biofluid concentrations, enzymes, genes, NMR orMS spectra
and disease information. The HMDB currently contains
7,985 compounds that are linked to 69,295 diﬀerent syn-
onyms. These compounds are also connected to 908 C-
NMR and 916 H-NMR spectra as well as 7,234 associated
enzymes. All chemical structures in these pathway maps are
hyperlinked to HMDB MetaboCards and all enzymes are
hyperlinked to UniProt data cards for human enzymes. The
majority of the compounds have been detected in blood
(4,226) while 784 compounds were detected in urine, 363
in CSF (cerebrospinal fluid) and 315 in other biofluids.
In order a compound to be included in the HMDB it
must fulfil certain criteria; it should be of biological origin,
the compound weight must be <1,500Da, and it should
be found at concentrations greater than 1mM in one or
more biofluids/tissues. Compounds that are not covered by
the above description but are either biomedically impor-
tant metabolites, like hormones, or certain very common
drugs and some ubiquitous food additives, like vitamins,
are some notable exceptions in the HMDB. For a large
number of metabolites the concentration values in the
biofluids are given with data for both normal and abnormal
values.
A key feature that distinguishes the HMDB from other
metabolic resources is its extensive support for higher
level database searching and selecting functions. More
than 175 hand-drawn-zoomable, fully hyperlinked human
metabolic pathway maps can be found in HMDB and all
these maps are quite specific to human metabolism and
explicitly show the subcellular compartments where specific
reactions are known to take place. As an equivalent to
BLAST the HMDB contains a structure similarity search
tool for chemical structures and users may sketch or
paste a SMILES string of a query compound into the
Chem-Query window. Submitting the query launches a
structure similarity search tool that looks for common
substructures from the query compound that match the
HMDB’s metabolite database. The wealth of information
and especially the extensive linkage to metabolic diseases
to normal and abnormal metabolite concentration ranges,
to mutation/SNP data and to the genes, enzymes, reactions
and pathways associated with many diseases of interest
makes the HMDB one the most valuable tool in the hands
of clinical chemists, nutritionists, physicians and medical
geneticists.
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Figure 1: Metabolomics holds the promise to deliver valuable information about biochemical pathways perturbed in disease and upon
treatment, to monitor healthy people to detect early signs of disease, to diagnose disease or predict the risk of a disease, to subclassify
disease, to make safer drugs by predicting the potential for adverse drug reactions, and to speed the discovery and development of novel drug
molecules.
Figure 2: A screenshot montage of the HMDB, SMPDB and T3DB databases.
2.2. The Small Molecule Pathway Database (SMPDB).
SMPDB consists of approximately 350 hand-drawn pathways
with more than 280 of them unique to SMPDB. These
pathways describe small molecule metabolism or small-
molecule processes that are specific to humans and fall
into four diﬀerent categories: (i) metabolic pathways; (ii)
small-molecule disease pathways, (iii) small molecule drug
pathways, and (iv) small molecule signalling pathways. In
order for a metabolic pathway to be suitable for inclusion in
SMPDB, it must be found in humans and it must contain
at least five small molecules. If it is a human disease, drug
or signalling pathway the determining factor for inclusion
is its central feature being based on the action of at least
one small molecule. More specifically, in SMPDB, disease
pathways refer to those pathways describing human disease
processes where small-molecule metabolite dysregulation is
the primary hallmark of the disease. For qualifying a small
molecule or set of small molecules to be included in SMPDB,
a significant concentration change, which is commonly used
for the diagnosis, prognosis, or monitoring for a given
disease, is required. The SMPDB interface is largely modelled
after the interface used for DrugBank and the HMDB with a
navigation panel for browsing, searching, and downloading
the database. The users can choose between two brows-
ing options, SMP-BROWSE, and SMP-TOC. The latter is
basically a scrollable hyperlinked table of contents that lists
all pathways by name and category. SMP-BROWSE is a
more comprehensive browsing tool that provides a tabular
synopsis of SMPDB’s content using thumbnail images of the
pathway diagrams, textual descriptions of the pathways, as
well as lists of the corresponding chemical components and
enzyme/protein components. All of the chemical structures
and proteins/enzymes illustrated in SMPDB’s diagrams are
hyperlinked to other online databases or tables, but this is
common inmost pathway databases. Specifically, all metabo-
lites, drugs or proteins shown in the SMP-BROWSE tables
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Table 1: Machine-learning algorithms often used in metabolomics.
Technique Description
PCA
The Principal Component Analysis (PCA) is a frequently used method which is applied to extract the systematic
variance in a data matrix. It helps to obtain an overview over dominant patterns and major trends in the data. The
aim of PCA is to create a set of latent variables which is smaller than the set of original variables but still explains all
the variance of the original variables. In mathematical terms, PCA transforms a number of correlated variables into a
smaller number of uncorrelated variables, the so-called principal components.
PLS
Partial Least Squares (PLS), also called Projection to Latent Structures, is a linear regressionmethod that can be applied
to establish a predictive model, even if the objects are highly correlated. The X variables (the predictors) are reduced
to principal components, as are the Y variables (the dependents). The components of X are used to predict the scores
on the Y components, and the predicted Y component scores are used to predict the actual values of the Y variables.
In constructing the principal components of X, the PLS algorithm iteratively maximizes the strength of the relation of
successive pairs of X and Y component scores by maximizing the covariance of each X-score with the Y variables. This
strategy means that while the original X variables may be multicollinear, the X components used to predict Y will be
orthogonal. Also, the X variables may have missing values, but there will be a computed score for every case on every
X component. Finally, since only a few components (often two or three) will be used in predictions, PLS coeﬃcients
may be computed even when there may have been more original X variables than observations.
O-PLS
The Orthogonal Projections to Latent Structures (O-PLS) is a linear regression method similar to PLS. However,
the interpretation of the models is improved because the structured noise is modeled separately from the variation
common to X and Y. Therefore, the O-PLS loading and regression coeﬃcients allow for a more realistic interpretation
than PLS, which models the structured noise together with the correlated variation between X and Y. Furthermore,
the orthogonal loading matrices provide the opportunity to interpret the structured noise.
PLS-DA
PLS-Discriminant Analysis (PLS-DA) is a frequently used classification method that is based on the PLS approach, in
which the dependent variable is chosen to represent the class membership. PLS-DA makes it possible to accomplish a
rotation of the projection to give latent variables that focus on class separation. The objective of PLS-DA is to find a
model that separates classes of objects on the basis of their X-variables. This model is developed from the training set
of objects of known class membership. The X-matrix consists of the multivariate characterization data of the objects.
To encode a class identity, one uses as Y-data a matrix of dummy variables, which describe the class membership. A
dummy variable is an artificial variable that assumes a discrete numerical value in the class description. The dummy
matrix Y has G collumns (for G classes) with ones and zeros, such that the entry in the gth column is one and the
entries in other columns are zero for observations of class g.
ANN
Artificial Neural Networks (ANN) is a method, or more precisely a set of methods, based on a system of simple
identical mathematical functions, that working in parallel yield for each multivariate input X a single or multiresponse
answer. ANN methods can only be used if a comparably large set of multivariate data is available which enables
ANN training by example and work best if they are dealing with nonlinear relationships between complex inputs and
outputs. Themain component of a neural network is the neuron. Each neuron has an activation threshold, and a series
of weighted connections to other neurons. If the aggregate activation a neuron receives from the neurons connected
to it exceeds its activation threshold, the neuron fires and relays its activation to the neurons to which it is connected.
The weights associated with these connections can be modified by training the network to perform a certain task. This
modification accounts for learning. ANN are often organized into layers, with each layer receiving input from one
adjacent layer, and sending it to another. Layers are categorized as input layers, output layers, and hidden layers. The
input layer is initialized to a certain set of values, and the computations performed by the hidden layers update the
values of the output layers, which comprise the output of the whole network. Learning is accomplished by updating the
weights between connected neurons. The most common method for training neural networks is back propagation,
a statistical method for updating weights based on how far their output is from the desired output. To search for
the optimal set of weights, various algorithms can be used. The most common is gradient descent, which is an
optimization method that, at each step, searches in the direction that appears to come nearest to the goal.
SOM
Self-Organizing Maps (SOM) or Kohonen network is an unsupervised neural network method which has both
clustering and visualization properties. It can be used to classify a set of input vectors according to their similarity.
The result of such a network is usually a two-dimensional map. Thus, SOM is a method for projecting objects from a
high dimensional data space to a two-dimensional space This projection enables the input data to be partitioned into
”similar” clusters while preserving their topology, that is, points that are close to one another in the multidimensional
space are neighbors in the two-dimensional space as well.
SVM
Support Vector Machines (SVM) perform classification by constructing an N-dimensional hyperplane that optimally
separates the data into two categories. A SVM model using a sigmoid kernel function is equivalent to a two-layer,
perceptron neural network. The task of choosing the most suitable representation is known as feature selection. A set
of features that describes one object is called a vector. The goal of SVM modeling is to find the optimal hyperplane
that separates clusters of vectors in such a way that objects with one category of the target variable are on one side of
the plane and objects with the other category are on the other size of the plane. The vectors near the hyperplane are
the support vectors.
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Table 1: Continued.
Technique Description
K-means
K-means is a classic clustering technique that aims to partition objects into k clusters. First, you specify k, that is, how
many clusters are being sought. Then, k points are chosen at random as cluster centers. All objects are assigned to their
closest cluster center according to the ordinary Euclidean distance metric. Next, the centroid, or mean, of the objects
in each cluster is calculated. These centroids are taken to be the new center values for their, respective clusters. Finally,
the whole process is repeated with the new cluster centers. Iteration continues until the same points are assigned to
each cluster in consecutive rounds, at which stage the cluster centers have stabilized.
Genetic
Algorithms
Genetic algorithms are nondeterministic stochastic search/optimization methods that utilize the evolutionary
concepts of selection, recombination or crossover, and mutation into data processing to solve a complex problem
dynamically. Possible solutions to the problem as so-called artificial chromosomes, which are changed and adapted
throughout the optimization process until an optimus solution is obtained. A set of chromosomes is called population
and creation of a population from a parent population is called generation. In a first step, the original population is
created. For each chromosome, the fitness is determined and a selection algorithm is applied to choose chromosomes
for mating. These chromosomes are then subject to the crossover, and the mutation operators, which finally yield a
new generation of chromosomes.
or in a pathway diagram are linked to HMDB, DrugBank
or UniProt, respectively. One of the most interesting search
options in SMPDB is the SMP-MAP which oﬀers both
multiidentifier searches as well as transcriptomic, proteomic,
or metabolomic mapping. SMP-MAP allows users to select
the type of “-omic” data, then paste in a list of identifiers and
have a table generated of appropriately highlighted pathways
containing those components.
The content of SMPDB is not normally found in other
pathway databases with 281 unique pathways (in total
of 364). More specifically, 154/168 drug pathways, 11/13
metabolite signalling pathways, 4/70 metabolic pathways
and 112/113 metabolic disease pathways of the SMPDB
cannot be found in any of the known databases (KEGG,
Reactome, EHMN, WikiPathways, HumanCyc, BioCarta,
and PharmGKB). Especially in relation to metabolic disease
pathways and drug pathways the SMPDB is currently the
only pathway database that includes significant numbers
of them. In addition SMPDB oﬀers a significant amount
of useful graphical content including the depiction of the
relevant organs, cellular locations, organelles, cofactors and
other cellular features. Because SMPDB is focused on small
molecules, it does not include the key protein signalling
pathway information which limits significantly its use in
comparative metabolic studies, protein network analysis,
metabolic engineering or metabolic evolution.
2.3. Toxin and Toxin-Target Database (T3DB). As the name
indicates, T3DB is primarily intended to be a database
that links toxins with their biological targets. However, the
molecular interaction information is further supplemented
with detailed descriptions of the toxin’s mechanism of action,
its metabolism in the human body, its lethal or toxic
dose levels, its potential carcinogenicity, exposure sources,
symptoms or health eﬀects and suggested treatment options.
More than 2,900 toxin entries corresponding to more than
34,000 diﬀerent synonyms are currently included in the
T3DB. T3DB toxins were identified using a number of meth-
ods that include data mining, literature surveys, toxicology
textbooks but also examining lists of controlled or banned
substances. The toxic compounds that were identified were
subsequently used to derive additional substances that were
toxic by relation. In order to ensure both completeness
and correctness each toxin record entered in T3DB was
reviewed by two diﬀerent members of the team. Much of
the annotation was done manually especially in areas such
as route of delivery, mechanisms of action, health eﬀects and
target identification.
T3DB contains compounds that have been routinely
identified as hazardous in relatively low concentrations
(<1mM for some, <1 μM for others) and which appear
on multiple toxin/poison lists provided by government
agencies such as TOXNET or the toxicological and medical
literature. In each case, the toxicity of each compound was
assessed by examining the available toxicity measurements
and health eﬀects, such as minimum lethal dose, LD50,
LC50 values and carcinogenicity. In addition these toxins
are further connected to approximately 1,300 protein targets
through almost 33,500 toxin and toxin-target bonds. All
the above information is supported by more than 3,100
references. To facilitate browsing, the T3DB is divided into
synoptic summary tables which, in turn, are linked to
more detailed “Tox-Cards”-in analogy to the very successful
“DrugCard” concept found in DrugBank. Each Tox-Card
entry contains over 80 data fields, with ∼50 data fields
devoted to chemical and toxicological/medical data and ∼
30 data fields devoted to describing the toxin target(s). In
addition to the data viewing and sorting features, the T3DB
also oﬀers a local BLAST search that supports both single
and multiple sequence queries, a boolean text search based
on KinoSearch (http://www.rectangular.com/kinosearch/), a
chemical structure utility based on ChemAxon’s Marvin-
View, and a relational data extraction tool similar to that
found in DrugBank and the HMDB. The SeqSearch, a
sequence searching utility of T3DB’s, provides the option to
search through T3DB’s collection of 1,300 known human
toxin targets. The SeqSearch makes possible the identifica-
tion of both orthologous and paralogous targets for known
toxins or toxin targets but facilitates also the identification
of potential targets of other animal species. The T3DB’s
data extraction utility employs a simple relational database
system that allows users to select one or more data fields and
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to search for ranges, occurrences or partial occurrences of
words, strings or numbers.
In comparison to other databases that contain toxic
substances T3DP probably has the smallest number of toxins
or poisons in its collection since T3DB was designed as
a database for common toxins and not for all known
toxic substances. A key focus of the T3DB is on providing
“depth” over “breath” and with its unique emphasis on
“common” substances should prove to be a valuable resource
in toxicometabolomics and clinical toxicology research.
3. Identification of Disease Biomarkers
In clinical metabolomics one is almost always working with
a biofluid or a fluidized tissue extract. The preference of
working with biofluids over tissues is primarily dictated by
the fact that fluids are far easier to process and analyze.
Likewise the collection of biofluids is generally much less
invasive than the collection of tissues. Biofluids analysis
is always done with the assumption that the chemicals
found in diﬀerent biofluids are largely reflective of the
biological state of the organ that produces or is bathed in
this fluid. Metabolomics share many of the computational
needs with genomics, proteomics, and transcriptomics. All
four “-omics” techniques require electronically accessible
and searchable databases, all of them require software to
handle or process data from their own high-throughput
instruments, all of them require laboratory information
systems to manage their data and all require software tools
to predict or model properties, pathways, relationships, and
processes [14]. In terms of data analysis, metabolomics,
like other functional genomics technologies, produces high-
dimensional datasets, and so it is amenable to many of the
analyses applied to microarray data. Statistical modelling
(Table 2) range from univariate statistical testing to mul-
tivariate regression methods such as principal component
analysis (PCA), partial least squares (PLS) or orthogonal pro-
jections to latent squares (OPLS), cluster analysis, machine-
learning techniques and nonlinear methods, for example
Kohonen’s self organizing maps (SOM), support vector
machines (SVM), and neural networks (NN) [15–18]. In
the following section we have chosen to focus on specific
applications that demonstrate how the above statistical
modelling tools can facilitate the diagnosis of diseases and the
identification of potential biomarkers for use within disease
diagnosis.
3.1. Cancer. The paper of Guan et al. [19] is the first appli-
cation of SVMs and SVM-related feature selection methods
(recursive feature elimination with linear and nonlinear ker-
nel, L1SVM, and Weston’s method) for classifying LC/TOF
MS data of serum samples from ovarian cancer patients and
control. Sera from 37 ovarian cancer patients and 35 benign
controls were studied and three evaluation processes (leave-
one-out-cross-validation, 12-fold-cross-validation, and 52–
20-split-validation) were used to examine the SVM models
based on selected potential metabolic diagnostic biomarkers
in terms of their ability for diﬀerentiating control versus
disease serum samples. Classification of the serum sample
test set was over 90% accurate indicating promise that this
approach may lead to the development of an accurate and
reliable metabolomic-based protocol for detecting ovarian
cancer.
The aim of another recent study [20] was to elucidate
the predictability of breast cancer by means of urinary
excreted nucleosides. The authors analyzed a balanced set of
170 urine samples, 85 breast cancer women and, respective
healthy controls, and after identification of 51 nucleosides/
ribosylated metabolites in the urine of breast cancer women
a valid set of 35 candidates was selected for subsequent
computational analysis. The bioinformatic tool of Oscillating
Search Algorithm for Feature Selection (OSAF) was applied
to iteratively improve features for training of SVMs to
better predict breast cancer. The authors found a reasonable
set of tumor-related metabolite pairs with SVM prediction
performance of 83.5% sensitivity and 90.6% specificity,
demonstrating that semiquantitative measurements are valu-
able for pattern detection using nonparametric machine-
learning algorithms.
Arakaki et al. [21] described CoMet, a fully automated
and general computational metabolomics method that uses a
Systems Biology approach to predict the human metabolites
which intracellular levels are more likely to be altered in
cancer cells. The authors then prioritize the metabolites
predicted to be lowered in cancer compared to normal cells as
potential anticancer agents. They discovered eleven metabo-
lites that either alone or in combination exhibit significant
antiproliferative activity in Jurkat leukemia cells. Nine of
these metabolites that were predicted to be lowered in Jurkat
cells with respect to lymphoblasts (riboflavin, tryptamine, 3-
sulfino-L-alanine, menaquinone, dehydroepiandrosterone,
α-hydroxystearic acid, hydroxyacetone, seleno-L-methionine
and 5,6-dimethylbenzimidazole) exhibited antiproliferative
activity that has not been reported before. These results
strongly suggest that many other metabolites with important
roles in cellular growth control may be waiting to be
discovered, opening up the possibility of novel approaches
against cancer. CoMet adopts the viewpoint that the cell
is an integrated machine and the author’s resulting simple
hypothesis that inspired its creation can greatly assist in the
understanding of the contribution of metabolism to this
complex disease.
In a diﬀerent approach using an animal model Southam
et al. [22] applied NMR-based metabolomics to histpatho-
logically well-characterized livers dissected from a wild-
caught species of marine flatfish. The use of metabolic profil-
ing and correlation networks enabled a more thorough inter-
pretation of this dataset. Fingerprint analysis identified single
metabolites that showed concentration changes between
phenotypes, while network analysis highlighted alterations to
the relationships of paired metabolites between phenotypes.
Tumor tissues showed elevated anaerobic respiration and
reduced TCA cycle activity, while alanine and proline were
indicated to supplement pyruvate (and NAD+) production
during anaerobic metabolism in the tumor tissue. Choline
metabolism was altered in tumor including disruptions
of the choline oxidation and CDP-choline pathways. The
author’s hypothesis was that such disruption of the choline
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Table 2: Freely available databases on metabolic pathways and the metabolome.
Metabolic Pathways Databases Webpage
BRENDA, the enzyme database, has comprehensive information
on enzymes and enzymatic reactions. It is one of several databases
nested within the metabolic pathway database set of the SRS5
sequence retreival system at EBI.
http://www.brenda.uni-koeln.de/
Reactome is an online bioinformatics database of biology
described in molecular terms. The largest set of entries refers to
human biology, but Reactome covers a number of other organisms
as well. It is an on-line encyclopedia of core human pathways-DNA
replication, transcription, translation, the cell cycle, metabolism,
and signaling cascades.
http://www.reactome.org/
KEGG Metabolic Pathways include graphical pathway maps for all
known metabolic pathways from various organisms. Ortholog
group tables, containing conserved, functional units in a molecular
pathway or or assembly, as well as comparative lists of genes for a
given functional unit in diﬀerent organisms, are also available.
http://www.genome.jp/kegg/metabolism.html
MetaCyc is a database of nonredundant, experimentally elucidated
metabolic pathways. MetaCyc contains more than 1,400 pathways
from more than 1,800 diﬀerent organisms, and is curated from the
scientific experimental literature. MetaCyc contains pathways
involved in both primary and secondary metabolism, as well as
associated compounds, enzymes, and genes.
http://metacyc.org/
The WIT Metabolic Reconstruction project produces metabolic
reconstructions for sequenced, or partially sequenced, genomes. It
currently provides a set of over 25 such reconstructions in varying
states of completion. Over 2900 pathway diagrams are available,
associated with functional roles and linked to ORFs.
http://ergo.integratedgenomics.com/
BioCarta website provides gene interactions in dynamic graphical
models. The online maps depicts molecular relationships and it
catalogs and summarizes important resources providing
information for more than 12,000 genes from multiple species. It
contains both classical pathways as well as suggestions for new
pathways.
http://main.biocarta.com/genes/index.asp
EcoCyc describes the genome and the biochemical machinery of E.
coli. It provides a molecular and functional catalog of the E. coli
cell to facilitates system-level understanding. Its Pathway/Genome
Navigator user interface visualizes the layout of genes, of
individual biochemical reactions, or of complete pathways. It also
supports computational studies of the metabolism, such as
pathway design, evolutionary studies, and simulations. A related
metabolic database is Metalgen.
http://ecocyc.org/
BioSilico is a web-based database system that facilitates the search
and analysis of metabolic pathways. Heterogeneous metabolic
databases including LIGAND, ENZYME, EcoCyc and MetaCyc are
integrated in a systematic way, thereby allowing users to eﬃciently
retrieve the relevant information on enzymes, biochemical
compounds and reactions. In addition, it provides well-designed
view pages for more detailed summary information.
http://mbel.kaist.ac.kr/lab/index ko.html
EXPASY - Biochemical Pathways is a searchable database of
metabolic pathways, enzymes, substrates and products. Based on a
given search, it produces a graphic representation of the relevant
pathway(s) within the context of an enormous metabolic map.
Neighboring metabolic reactions can then be viewed through links
to adjacent maps.
http://www.expasy.ch/cgi-bin/search-biochem-index
BioPath is a database of biochemical pathways that provides access
to metabolic transformations and cellular regulations derived from
the Roche Applied Science ”Biochemical Pathways” wall chart.
BioPath provides access to biological transformations and
regulations as described on the ”Biochemical Pathways” chart.
http://www.molecular-networks.com/biopath/
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Metabolic Pathways Databases Webpage
BioCyc is a collection of 505 Pathway/Genome Databases. Each
database in the BioCyc collection describes the genome and
metabolic pathways of a single organism. The BioCyc Web site
contains many tools for navigating and analyzing these databases,
and for analyzing omics data, including the following: Genome
browser, Display of individual metabolic pathways, and of full
metabolic maps, Visual analysis of user-supplied omics datasets by
painting onto metabolic map, regulatory map, and genome map,
Comparative analysis tools.
http://biocyc.org/
Metabolome Databases Webpage
The Biological Magnetic Resonance Data Bank (BMRB) focuses on
quantitative data generated by spectroscopic investigations of
biological macromolecules. It has links to search engines such as
PubChem, that connect to recent articles and new data. It also links
to projects and other databases that are all related to Metabolomics
and Metabonomics. This database focuses on the NMR research
aspect of metabolites discovery and their role in metabolism.
http://www.bmrb.wisc.edu/metabolomics/
The Madison Metabolomics Consortium Database contains
metabolites determined through NMR and MS. It contains
information with the main focus on Arabidopsis thaliana, but also
refers to many diﬀerent species. The database also contains
information on the presence of metabolites under several diﬀerent
physiological conditions, their structures in 2D and 3D, and links
to related resource sources and other databases.
http://mmcd.nmrfam.wisc.edu/
The Human Metabolome Database is an extremely comprehensive,
free electronic database that gives a detailed overview of human
metabolites divided into chemical, clinical, and molecular
biology/biochemistry data.
http://www.hmdb.ca/
KNApSAcK is a Java application that presents an interactive
display of biochemical information that can be searched by
organism or metabolite name. KNApSAcK focuses primarily on
the origin and mass spectra of particular metabolites.
http://kanaya.naist.jp/KNApSAcK
The BiGG database is a metabolic reconstruction of human
metabolism designed for systems biology simulation and
metabolic flux balance modeling. It is a comprehensive
literature-based genome-scale metabolic reconstruction that
accounts for the functions of 1,496 ORFs, 2,004 proteins, 2,766
metabolites, and 3,311 metabolic and transport reactions. It was
assembled from build 35 of the human genome.
http://bigg.ucsd.edu/
SetupX, developed by the Fiehn laboratory at UC Davis, is a
web-based metabolomics LIMS. It is XML compatible and built
around a relational database management core. It is particularly
oriented towards the capture and display of GC-MS metabolomic
data through its metabolic annotation database called BinBase.
http://fiehnlab.ucdavis.edu:8080/m1/
McGill-MD is a metabolome database containing metabolite mass
spectra of organisms; with abiotic/biotic stress or in homeostasis.
Users are able to obtain a table containing the metabolome of an
organism, or download mass spectra of all the metabolites entered
in the database.
http://metabolomics.mcgill.ca/
SYSTOMONAS (SYSTems biology of pseudOMONAS) is a
database for systems biology studies of Pseudomonas species. It
contains extensive transcriptomic, proteomic and metabolomic
data as well as metabolic reconstructions of this pathogen.
Reconstruction of metabolic networks in SYSTOMONAS was
achieved via comparative genomics. Broad data integration with
well established databases BRENDA, KEGG and PRODORIC is
also maintained.
http://www.systomonas.de/
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Metabolic Pathways Databases Webpage
MassBank is a mass spectral database of experimentally acquired
high resolution MS spectra of metabolites. Maintained and
supported by the JST-BIRD project, it oﬀers various query
methods for standard spectra obtained from Keio University,
RIKEN PSC, and other Japanese research institutions. It is
oﬃcially sanctioned by the Mass Spectrometry Society of Japan.
The database has very detailed MS data and excellent
spectral/structure searching utilities. More than 13,000 spectra
from 1900 diﬀerent compounds are available.
http://www.massbank.jp/
The Golm Metabolome Database provides public access to custom
GC/MS libraries which are stored as Mass Spectral (MS) and
Retention Time Index (RI) Libraries (MSRI). These libraries of
mass spectral and retention time indices can be used with the
NIST/AMDIS software to identify metabolites according their
spectral tags and RI’s. The libraries are both searchable and
downloadable and have been carefully collected under defined
conditions on several types of GC/MS instruments (quadrupole
and TOF).
http://csbdb.mpimp-golm.mpg.de/csbdb/gmd/gmd.html
The METLIN Metabolite Database is a repository for mass spectral
metabolite data. All metabolites are neutral or free acids. It is a
collaborative eﬀort between the Siuzdak and Abagyan groups and
Center for Mass Spectrometry at The Scripps Research Institute.
METLIN is searchable by compound name, mass, formula or
structure. It contains 15,000 structures, including more than 8000
di and tripeptides. METLIN contains MS/MS, LC/MS and FTMS
data that can be searched by peak lists, mass range, biological
source and or disease.
http://metlin.scripps.edu/index.php
oxidation pathway could lead to reduced SAM produc-
tion and potentially DNA hypomethylation of oncogenes.
3.2. Diabetes. The paper of Altmaier et al. [23] presents
a bioinformatics analysis of what can be considered as a
standard experimental setting of a preclinical drug test-
ing experiment with two independent factors, “state” and
“medication”. Targeted quantitative metabolomics covering
a wide range of more than 800 relevant metabolites were
measured in blood plasma samples from healthy and diabetic
mice under rosiglitazone (a member of thiazolidinedione)
treatment. The authors show that known and new metabolic
phenotypes of diabetes and medication can be recovered
in a statistically objective manner. Analyzing ratios between
metabolite concentrations dramatically reduces the noise in
the data set allowing the discovery of new potential biomark-
ers of diabetes, such as the N-hydroxyacyloylsphingosyl-
phosphocholines SM(OH)28 : 0 and SM(OH)26 : 0. Using
a hierarchical clustering technique on partial η2 values the
authors identified functionally related groups of metabo-
lites, indicating a diabetes-related shift from lysophospho-
phatidylcholine to phosphatidylcholine levels.
Coupled LC/MS technology to multivariate statistical
analysis in order to study phospholipid metabolic profiling
in diabetes mellitus and to discover the potential biomarkers
was the approach of Wang et al. [24]. PCA and PLS-
DA models were compared in class separation of type
2 diabetes mellitus (DM2) patients and healthy controls.
Uv (unit variance) scaling and OSC (orthogonal signal
correction) data preprocessing methods were also developed
to improve class separation. Using the supervised PLS-DA
algorithm with Uv scaling and OSC technique on the data
set, it was found that the separation of diﬀerent classes was
highly improved (compared to PCA analysis) particularly
with OSC. The application of LC/MS coupled to PLS-DA of
data with OSC scaling made it possible to classify DM2 and
control and further to discover potential biomarkers that can
be identified by MS/MS.
NMR-based metabolomics coupled with sophisticated
bioinformatics was shown capable of identifying rapid
changes in global metabolite profiles in urine and plasma
(treatment “fingerprints”) which may be linked to the well-
documented early changes in hepatic insulin sensitivity
following thiazolidinedione intervention in Type 2 diabetes
mellitus [12]. Several endogenous metabolites in urine and
plasma of T2DM patients that responded to rosiglitazone
treatment were identified. In urine these changes were related
to a gender-independent relative reduction of hippurate and
a further increase of aromatic acids. The gender-dependent
changes observed in plasma samples included an increase in
branched chain amino acids, alanine, glutamine/glutamate
and citrate, coinsiding with a decrease in lactate, acetate,
tyrosine, and phenyalanine in the female T2DM group,
where changes in the male T2DM group included an increase
in branched chain amino acids, alanine, glutamine, and
threonine. A good distinction between diabetic patients
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and healthy volunteers as well as separation by gender
was accomplished when Supervised Principal Component
Discriminant Analysis (PC-DA) of plasma or urine samples
was applied which comprises an important new addition to
the early clinical development “proof of concept” toolbox for
thiazolidinediones.
Diabetes is associated with increased incidence of vas-
cular complications, and premature aging. In the study of
Makinen et al. [25], the emphasis was on the metabolic
continuum that underlies the slow and often elusive devel-
opment of chronic complications. The authors obtained
serum samples to measure two molecular windows, —the
lipoprotein lipids (LIPO) window and the low molecular
weight molecules (LMWM)—for 613 patients with type I
diabetes, and diverse spread of complications. The H-NMR
analyses combined with SOM instead of linear decomposi-
tion methods allowed the authors to transform the spectral
data into an accesible form of information. The work of
Makinen et al. demonstrated the limitations of single diag-
nostic biomarkers and illustrated a fundamental diagnostic
challenge. Even though there is a common biochemical
basis of diabetic kidney disease, diabetic retinal disease, the
metabolic syndrome, and macrovascular diseases however
they do not conclusively define each other.
Salek et al. [26] describe the application of 1H-NMR
spectroscopybased metabolomics, combined with multi-
variate and univariate statistics, to investigate the urinary
metabolic profiles in two animal models (mice and rat)
of T2DM, and they compared these metabolic changes
with perturbations observed in a human population. This
study demonstrated metabolic similarities between the three
species examined. Along with the expected changes in
hepatic glycolysis/ gluconeogenesis changes in the excretion
of TCA cycle intermediates, polyols, amines, and amino
acids were detected. Furthermore significant changes in
pyruvate and fatty acid metabolism as well as hepatic
amino acid metabolism were observed including trypto-
phan metabolism. A profound perturbation in nucleotide
metabolism, previously linked with peroxisome prolifer-
ation, was also observed and may indicate a metabolic
consequence of substrate excess in many tissues, especially
the liver.
In the study of Connor et al. [27], the authors have
generated NMR-basedmetabolomic and transcriptomic data
from the db/db diabetic mouse, one of the most exten-
sively studied animal models of T2D. Db/db mice lack a
functioning leptin receptor resulting in defective leptin-
mediated signal transduction. Metabolomics data identified
24 distinct pathways that were altered in the diabetic mice
when compared to their euglycaemic littermates. Several of
these pathways were related to known disease eﬀects, but
in addition novel eﬀects on branched chain amino acid
metabolism, nicotinamide metabolites, pantothenic acid,
and gut microflora metabolism were also observed. Inte-
grative pathway analysis of the metabolite-centric networks
and the cross-platform transcriptomics and metabolomics
results eﬀectively linked many of the metabolite changes to
pathways involved in gluconeogenesis, and those generating
substrates for gluconeogenesis, mitochondrial dysfunction
and oxidative stress, and altered protein turnover. Overall,
thesemetabolites are likely reflective of additional underlying
pathophysiology that is present in T2D.
The objective of Lanza et al. [28] was to illustrate
the utility of a combination of analytical methods and
multivariate statistical analysis for detecting a metabolic
fingerprint that reflects known pathways that are altered
with insulin deficiency. The authors analyzed plasma from
type 1 diabetic (T1D) humans during insulin treatment
(I+) and acute insulin deprivation (I−) and nondiabetic
participants (ND) and they generated correlation matrices
for the plasma metabolites measured by both MS and NMR
to create a compendium metabolic profile that integrates
the complementary information from the two analytical
methods. Multivariate statistics diﬀerentiated proton spectra
from I− and I+ based on several derived plasma metabo-
lites that were elevated during insulin deprivation (lactate,
acetate, allantoin, and ketones) as well as several underlying
physiological processes that are known to be altered by
short-term insulin deprivation in type 1 diabetic people
(e.g., mitochondrial dysfunction, oxidative stress, protein
synthesis, degradation, and oxidation, gluconeogenesis, and
ketogenesis).
Bao et al. [29] performed a metabonomic study to deter-
mine metabolic variations associated with T2DM and the
drug treatments on 74 patients who were newly diagnosed
with T2DM and received a 48-week treatment of a single
drug, repaglinide, metformin, or rosiglitazone. A total of 212
individual metabolites were consistently detected in at least
90% of the serum samples and orthogonal projections to
latent structures discriminant analysis, a newly developed
supervised pattern recognition method, was used to capture
the subtle intergroup variations and establish a prediction
model to assess the physiological impact by drug treat-
ment. As compared to healthy controls, the altered serum
metabolites in diabetic subjects, include the significantly
increased valine, maltose, glutamate, urate, butanoate, and
long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate,
and arachidonate), and decreased glucuronolactone, lysine,
and lactate suggesting a hypercatabolic state in T2DM
patients. Rosiglitazone treatment was able to reverse more
abnormally expressed metabolites, such as valine, lysine,
glucuronolactone, C16:0, C18:1, urate, and octadecanoate,
than the other two drugs.
Cˇuperlovic´-Culf [30] presented an application of fuzzy
K-means (F-KM) method for the classification of metabolic
profiles of urine samples in diabetic patients. F-KM is a
fuzzy version of standard K-means clustering. In F-KM
clustering, each sample has an overall membership, that
is, sum of membership values for all clusters, of 1. This
overall membership is appointed to clusters based on the
similarity between the sample’s metabolic fingerprint and the
profile of cluster’s centroid. From the membership values, it
is then possible to determine diﬀerent levels of coclustering
between samples-based on the top membership, second
highest membership, and so forth. In their work diﬀerent
clustering methods were compared with F-KM. For human
type II diabetes and healthy phenotypes membership values,
F-KM lead to better sample separation while it was the only
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method that allowed distinction on both major groups and
sample subtypes.
3.3. Neurological and Other Diseases. The study of Rozen
et al. [4] was designed to assess whether there are systematic
diﬀerences between redox-active metabolites in the blood
of patients with motor neuron disease (MND) and healthy
controls by analyzing the blood plasma of 30 healthy
controls and 28 individuals with MND. To determine which
metabolites were significantly elevated or reduced in MND
the authors used three measures of class association, the t-
statistic, Pearson’s correlation coeﬃcient, and the “relative
class association” measure. All three measures produced sim-
ilar rankings of their metabolites by their level of association
with MND versus control. The authors assessed statistical
significance by permutation testing and all measures showed
similar numbers of metabolites to have significantly higher
or lower concentrations in MND compared to controls.
Subsequently they analyzed these data to determine if the
metabolites were capable of distinguishing four subgroups
(normal controls MND patients taking riluzole medica-
tion, MND without riluzole medication, and the subgroup
enriched for LMN-lower motor neuron disease) using the
317 metabolite concentrations. Using PLS-DA, a supervised
projection technique, the authors found a three-dimensional
projection in which these four subgroups were significantly
separated.
1H nuclear magnetic resonance spectroscopy in con-
junction with computerized pattern recognition analysis
were employed to investigate metabolic profiles of a total
of 152 cerebrospinal fluid (CSF) samples from drug-naı¨ve
or minimally treated patients with first-onset paranoid
schizophrenia and healthy controls [7]. Plots of PLS-DA
scores showed a clear diﬀerentiation between healthy vol-
unteers and drug-naı¨ve patients. The PLS-DA score plots
show that atypical antipsychotic drug treatment results in
a shift of approximately 50% of patients with schizophrenia
towards the cluster of healthy controls. A striking finding of
this study is the eﬀect of the number of psychotic episodes
prior to commencing antiphychotic treatment on the CSF
metabolite profile in patients with schizophrenia. Of 21
patients who commenced antipsychotic medication during
their first psychotic episode, 57% clustered with healthy
controls whereas six out of the seven patients who had several
psychotic episodes prior to treatment clustered with the
group of drug-naı¨ve patients with first-onset schizophrenia.
These results suggest that the initiation of antipsychotic
treatment during a first psychotic episode may influence
treatment response and/or indeed outcome.
Pre-eclampsia is an important cause of maternal mor-
bidity and mortality while the World Health Organization
estimates that worldwide over 100,000 women die from pre-
eclampsia each year. By using GC-tof-MS the authors [31]
were able to separate and detect several hundred metabolites
from both control (87) and diseased (87) samples. The
application of genetic algorithms on these data indicated
that the pre-eclamptic plasma could be discriminated from
the matched controls on the basis of just three metabolite
peaks (two of which tended to be lower and one tended to
be higher in the samples from women with pre-eclampsia,
and to a certain extent this correlated with the severity of
the disease). In this context it is worth commenting that
genetic algorithms is advantageous over other machine-
learning methods such as neural networks and support
vector machines, as it allows one to understand the problem
in terms of small subsets of input variables that it combines
into rules. In the case of Kenny and colleagues [31], only
10 of each the disease and control samples were taken at a
gestational age of under 30 weeks, and a clear task for the
future is to establish the extent to which these diagnostic
rules apply earlier in pregnancy and thus are of greater
prognostic value.
A metabolic “bioprofile” consisting of predictive serum
metabolite features from 1H NMR spectral data of the
murine K/BxNmodel of arthritis were presented in the study
of Weljie et al. [32]. A unique method was developed by
combining technologies such as quantitative targeted profil-
ing, O-PLS-DA pattern recognition analysis and metabolic-
pathway-based network analysis for interpretation of results.
In total, 88 spectral features were profiled (59 metabolites
and 28 unknown resonances). A highly significant subset
of 18 spectral features (15 known compounds and 3
unknown resonances) was identified and in this metabolic
bioprofile, metabolites relating to nucleic acid, amino acid,
and fatty acid metabolism, as well as lipolysis, reactive
oxygen species generation, and methylation were among
them. Pathway analysis suggested a shift from metabolites
involved in numerous reactions (hub metabolites) toward
intermediates and metabolic endpoints associated with
arthritis.
4. Metabolomics in Drug Discovery and
Polypharmacology Studies
Drug molecules generally act on specific targets at the
cellular level, and upon binding to the receptors, they exert
a desirable alteration of the cellular activities, regarded as
the pharmaceutical eﬀect. Current drug discovery depends
largely on ransom screening, either high-throughput screen-
ing (HTS) in vitro, or virtual screening (VS) in silico. Because
the number of available compounds is huge, several drug-
likeness filters are proposed to reduce the number of com-
pounds that need to be evaluated. The ability to eﬀectively
predict if a chemical compound is “drug-like” or “nondrug-
like” is, thus, a valuable tool in the design, optimization, and
selection of drug candidates for development [33]. Drug-
likeness is a general descriptor of the potential of a small-
molecule to become a drug. It is not a unified descriptor
but a global property of a compound processing many
specific characteristics such as good solubility, membrane
permeability, half-life, and having a pharmacophore pat-
tern to interact specifically with a target protein. These
characteristics can be reflected as molecular descriptors
such as molecular weight, log P, the number of hydrogen-
bond donors, the number of hydrogen-bond acceptors, the
number of rotatable bonds, the number of rigid bonds, the
number of rings in a molecule, and so forth [34]. Lipinski’s
widely used rule of 5 defines drug-like “as those compounds
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that have suﬃciently acceptable absorption, distribution,
metabolism, excretion, and toxicity (ADMET) properties
to survive through the completion of Human Phase I
clinical trials” [35]. It has been observed that metabolites
tend to obey in their majority the Lipinski “Rule of 5”,
which hints to the fact that drugs are indirectly synthesized
to mimic the original endogenous substrates [36]. Based
on this, metabolite-likeness and biological relevance filters
have recently been developed, which consider that chemical
compounds from virtual screens of large pharmaceutical
libraries that are similar to endogenous metabolites stand
more chances for being successful drug candidates [37, 38].
The approach leverages the “chemical similarity principle”,
which states that molecules with similar structure likely have
similar biological properties.
Drug developers have long-mined small-molecule
metabolism for the design of enzyme inhibitors chemically
similar to their endogenous substrates. The approach has
yielded many successes, including antimetabolites such
a folate derivatives used in cancer therapy [39] and the
nucleoside analog prodrugs used for antiviral therapy [40].
With the recent availability of databases of metabolites and
metabolic reactions, we have gained a wealth of information
regarding the interaction of small molecules with biological
systems. At the same time, the notion of chemical space and
the advance of chemoinformatics tools have paved the way
to link the metabolome with structural and physicochemical
properties of endogenous metabolites and to predict links
between synthetic molecules and human metabolism.
Recent developments in the area of systems biology have
lead scientists to realize the limitations of reductionism and
begin to lay emphasis on more holistic research patterns,
such as systems biology and network pharmacology [41–44],
Most diseases are not caused by changes in a single causal
gene but by an unbalanced regulating network resulting
from the dysfunctions of multiple genes or their products.
At the same time, drug molecules commonly participate in
biological networks and both their intended eﬀect and side
eﬀect are rather systemic than specific to a single biological
target.
On this direction, Corey Adams and coworkers have
recently demonstrated a new method to predict what
enzymes drugs might aﬀect based on the chemical similarity
between classes of drugs and the natural chemicals used by
enzymes. The authors have applied themethod to 246 known
drug classes and a collection of 385 organisms to create maps
of potential drug action onmetabolism.Moreover, they show
how the predicted connections can be used to find new ways
to kill pathogens and to avoid unintentionally interfering
with human enzymes [45].
In the work of Macchiarulo and coworkers, human
metabolic pathways are projected and clustered on the
chemical space based on similarity of the involved metabo-
lites translated in a set of selected physicochemical and
topological descriptors. Further to this, the authors develop
a classifier that estimates the proximity of marketed drugs
to any given pathway, with the aim to elucidate the extend
of overlap and to uncover cross-interactions between drugs
and the major human pathways. The model performs well
for tightly clustered, isolated pathways, but it loses its
predictive ability when it comes to overlapping pathways
[46].
5. Metabolomics for the Study of
Polypharmacology of Natural Compounds.
Internationally, there is a growing and sustained interest
from both pharmaceutical companies and public inmedicine
from natural sources. For the public, natural medicine
represent a holistic approach to disease treatment, with
potentially less side eﬀects than conventional medicine. For
the pharmaceutical companies, bioactive natural products
constitute attractive drug leads, as they have been optimized
in a long-term natural selection process for optimal interac-
tion with biomolecules. To promote the ecological survival
of plants, structures of secondary products have evolved to
interact with molecular targets aﬀecting the cells, tissues
and physiological functions in competing microorganisms,
plants, and animals. In this, respect, some plant secondary
products may exert their action by resembling endoge-
nous metabolites, ligands, hormones, signal transduction
molecules, or neurotransmitters and thus have beneficial
eﬀects on humans due to similarities in their potential target
sites [47].
Complementary to the above studies on drug polyphar-
macology and in order to elucidate the extend of overlap
and similarity between natural compounds from plants
used in ethnomedicine and human metabolites, we created
chemical networks between natural compounds from the
Chinese Natural Products Database (CNPD v.2004.1) and
human metabolites from HMDB. CNPD is a compilation
of 57,346 compounds found in plants largely used in TCM
(Traditional Chinese Medicine). These compounds come
from 2,611 plant species belonging to 457 diﬀerent plant
genera. After removal of salts, inorganic compounds, and
duplicates, we extracted 53,180 unique, organic compounds
in SDF format, which we imported into a Molecular
Operating Environment (MOE, v.2008.10) [48] database.
1417 of these compounds are annotated with experimentally
derived bioactivity information. HMDB v. 2.5 was used as
source of human metabolites and 7,985 compounds were
extracted in SDF format. All structures were washed, that
is all ionizable groups were coordinated with neutral pH
conditions, and energy minimized using the MMFF946 force
field.
To get a first overview, we compared the two databases
considering common descriptors for drug-like molecules,
namely molecular weight (MW), number of hydrogen-bond
donors (HB donors), number of hydrogen-bond acceptors
(HB acceptors), number of rings and number of rotatable
bonds. As seen in the violin plots of Figure 3, the human
metabolites have higher average molecular weight (MW =
661.2) and broader distribution (std dev = 403.4), which
is obviously due to the presence of many lipids (3800 out
of 7985 compounds are lipids in the newest version of the
HMDB) [49]. The number of HB-donors is almost the same
in both CNPD and HMDB sets, with an average value of 2.4
and 2.5, respectively and 90% of the compounds in each data
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Figure 3: Comparison of the distribution of selected druglike molecular properties for natural compounds from CNPD and human
metabolites from HMDB. Violin plots for (a) molecular weight, (b) hydrogen-bond donors, (c) hydrogen-bond acceptors, (d) number
of rings and (e) number of rotatable bonds, along with table with mean values and standard deviations. A violin plot is a combination of a
box plot and a kernel density plot and oﬀers a more detailed view of a dataset’s variability than a box plot alone. The white marker indicates
the median of the data and the black box the interquirtile range (the diﬀerence between the third and first quartiles that contain 50% of the
distribution). The black lines extend to one and a half times the width of the box. Violin plots were made in R.
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set having ≤5 HB-donors. When it comes to HB-acceptors,
the two profiles diﬀer slightly. 90% of the compounds in
each data set have ≤10 HB-acceptors, but there is higher
percentage of human metabolites with 9-10 HB-acceptors
(6.9%) than are natural compounds (4.7%). Due to this,
CNPD has a lower mean value and std deviation (4.8 and
4.6, respectively). The number of rings is lower in HMDB,
again because of the presence of lipids that are acyclic. As
a consequence, compounds from HMDB have on average
many more rotatable bonds than their counterparts from
CNPD. While 95% of compounds from CNPD have up to 15
rotatable bonds, half of the compounds from HMDB have
between 30 and 50 rotatable bonds.
Despite the diﬀerences noted above, there is a significant
room for overlap between the chemical spaces of the two
datasets, which we attempt to elucidate via a more thorough
structural similarity analysis that follows. First we investigate
how many compounds are present in both data sets, by
comparing their SMILES (Simplified Molecular Input Line
Entry Specification) strings. Following that, we analyze the
extend of structural similarity of the two data sets. For this,
all pairs of molecules between the two sets are compared
using a pairwise similarity metric, which consists of a
descriptor and a similarity criterion. For the descriptor,
MACCS (Molecular ACCess System) keys were calculated in
MOE. The MACCS keys represent each molecule as a vector
of 166 bits, each indicating the presence or absence of a
predefined substructure or functional group (e.g., aromatic
rings, oxygens, amine groups, etc.). The similarity criterion
is the widely used Tanimoto coeﬃcient (Tc) [50]. Tc is
calculated as shown in (1). If two molecules have a and b bits
in their fragment bit-strings, respectively, with c of these bits
being present in both their fingerprints, then Tc corresponds
to the ratio of the number of bits the two molecules have
in common to the total number of occupied bins by both
molecules
Tc = c
a + b − c . (1)
Tc gives valules in the range of zero (no bits in common,
0% similarity) to unity (all bits the same, 100% similarity).
The Tc threshold for two compounds being similar was set
to 0.85 and the similarity networks were visualized using the
Organic Layout of Cytoscape v. 2.6.3 [51].
5.1. Overlap between Human Metabolites and Natural Com-
pounds. There are 383 compounds shared between the two
databases, which denotes that, apart from participating
in the human metabolism, these natural compounds are
secondary metabolites of plants used in ethnopharmacology.
For example, 2-pyrocatechuic acid (HMDB00397) is a
normal human benzoic acid metabolite found in plasma
that is an intermediate of the phenyl propanoid biosyn-
thesis. It is has been isolated from black currant [52],
which has long been used in European and Chinese folk
medicine as diuretic, treating diarrhea, arthritic pain, and
so forth. Recently, 2-pyrocatechuic acid was found to be
weak inhibitor of Selectin E [53] and potent inhibitor of
15-lipogygenase-catalysed oxygenation of arachidonic acid
that is involved in many aspects of inflammatory disease
and in particular in the development of colorectal cancer
[54].
Another example, indole (HMDB00738), is an aromatic
heterocyclic organic compound that occurs naturally in
human feces and has an intense fecal smell. At very low
concentrations, however, it has a flowery smell and is a
constituent of many flower scents. Natural jasmine oil that
contains around 2.5% of indole is used traditionally for
healing the female reproducing system, to treat headaches
and insomnia. In human metabolism, indole participates in
the tryptophan metabolic pathway, which is a highly regu-
lated biological process. There has been significant research
on the medical implications involved in dysregulation of
tryptophan metabolism. Abnormalities in it may play a
role in central nervous system diseases such as acquired
immunodeficiency syndrome- (AIDS-) related dementia
[55], Huntingtom’s disease [56] and psychopathological
disorders [57]. In addition, data from the literature suggest
that a mechanism dependent on tryptophan catabolism
might regulate the immune responses to a number of diseases
[58–60].
5.2. Similarity Networks of Human Metabolites and Natural
Compounds. There are 15,523 natural compounds in CNPD
(29% of the total data set) that have a Tanimoto similarity
coeﬃcient of 0.85 or higher with at least one human
metabolite. In total, there are formed 233,211 similarity
pairs between the two datasets, which indicates that each
natural compound is similar—on average—with 15 human
metabolites.
As an illustrative example, Figures 4 and 5 below show the
similarity networks of 2-pyrocatechuic acid and indole that
were discussed in the previous section. As seen in Figure 4,
2-pyrocatechuic acid is linked with Tc ≥ 0.9 to seven other
human metabolites and 28 natural compounds from CNPD.
Interestingly, the human metabolites of this similarity net-
work belong to two main metabolic processes. HMDB01866,
HMDB06242, HMDA00152, and HMDB01856 are involved
in tyrosine metabolism/biosynthesis, while HMDB00397,
HMDB03501, and HMDB01964 are intermediates of the
phenyl propanoid biosynthesis. Recent research on tyrosine
metabolism suggests strong correlation with chronic kidney
failure [61], eating disorders and migraine [62]. The natural
compounds from CNPD that are met in the network are
primarily benzoic acid derivatives from diverse sources of
plants (e.g., picea maximowiczii, grevillea robusta), fungi
(e.g., polyporus tumulosus, boletus scaber) and flowers (e.g.,
centaurium erythraea, anthemis nobilis), many of which are
known as folk medicine.
Indole, shown in Figure 5, is linked to one other
human metabolite, and four natural compounds from
CNPD. HMDB00466 is the compound 3-methyl indole
that is involved in tryptophan metabolism as well. Three
natural compounds from CNPD have high similarity to the
two human metabolites. 1-methyl-9H-carbazole (cas: 6510-
65-2), 3-methyl-9H-carbazole (cas: 4630-20-0) and 2,4-
dimethyl-1H-indole (cas: 10299-61-3) are alkaloids found in
Tedania ignis (a sponge species) [63], glycosmis pentaphylla
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Figure 4: Similarity network of 2-pyrocatechuic acid. Pink nodes indicate humanmetabolites fromHMDB and green nodes indicate natural
compounds from CNPD. Node labels denote the respective ID codes of the compounds. The nodes are linked when the two compounds have
Tc ≥ 0.85. Due to the high number of pairs with similarity between 0.85 and 0.90, we included in the figure only connections of Tc ≥ 0.90
to allow better visualization of the network. The width and color of the edges are analogous to the value of Tc: Cyan: 0.90 ≤ Tc < 0.95, Blue:
0.95 ≤ Tc < 1.0, Black: Tc = 1. The two nodes in yellow denote 2-pyrocatechuic acid with HMDB ID and CAS registry number, respectively.
(orangeberry) [64], and Tricholoma virgatum (a muchroom
species) [65], respectively. These natural compounds from
CNPD that are found similar to well-studied humanmetabo-
lites are potentially interesting leads with druglike and
metabolite-like properties that would be worth investigating
further for their medicinal properties and their impact on
human health.
In order to evaluate how the 29% similarity of CNPD to
HMDB compares with other types of data sets, we performed
the same analysis for 4,567 approved and experimental drugs
from DrugBank v.2, as well as for a randomly selected
subset of 59,025 compounds from ChemDiv, a commercial
provider of small compounds for drug discovery HTS. Quite
remarkably, the compounds from DrugBank showed the
same extend of similarity to HMDB as natural compounds
from CNPD. 1,331 drug compounds (29%) were found to
be similar to human metabolites, forming 35,635 similarity
pairs. On the other hand, only 182 compounds from the
subset of ChemDiv were found similar to any human
metabolite, forming just 1,563 similarity pairs in total.
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Figure 5: Similarity network of indole. Pink nodes indicate human metabolites from HMDB and green nodes indicate natural compounds
from CNPD. Node labels denote the respective ID codes of the compounds. The nodes are linked when the two compounds have Tc ≥ 0.85.
The width and color of the edges are analogous to the value of Tc: Cyan: 0.85 ≤ Tc < 0.95, Black: Tc = 1. The node in yellow denotes indole
with HMDB ID and CAS registry number, respectively.
This low similarity of ChemDiv could be attributed to
the fact that HTS databases contain small molecules with
simple structures that can be easily modified further to
more potent drug candidates. These finding supports the
hypothesis that as drug candidates move forward on the drug
optimization platform, there is favorable selection towards
those that mimic the endogenous substrates. The fact that
natural compounds also resemble the latter may indicate that
plants with medicinal properties may exert their action via
their molecular components resembling human endogenous
metabolites.
6. Future Perspectives
Metabolomics, the study of metabolism at the global level, is
moving to exciting directions.With the development of more
sensitive and advanced instrumentation and computational
tools for data interpretation in the physiological context,
metabolomics have the potential to impact our understand-
ing of molecular mechanisms of diseases. A state-of-the-
art metabolomics study requires knowledge in many areas
and especially at the interface of chemistry, biology, and
computer science. High-quality samples, improvements in
automated metabolite identification, complete coverage of
the human metabolome, establishment of spectral databases
of metabolites and associated biochemical identities, inno-
vative experimental designs to best address a hypothesis, as
well as novel computational tools to handle metabolomics
data are critical hurdles that must be overcome to drive the
inclusion of metabolomics in all steps of drug discovery and
drug development. The examples presented above demon-
strated that metabolite profiles reflect both environmental
and genetic influences in patients and reveal new links
betweenmetabolites and diseases providing needed prognos-
tic, diagnostic, and surrogate biomarkers. The integration of
these signatures with other omic technologies is of outmost
importance to characterize the entire spectrum of malignant
phenotype.
Systems chemical biology networks that assemble and
integrate known and predicted links between small com-
pounds of biological relevance, including human metabo-
lites, can have a great potential in pharmaceutical research
that could be used in a variety of ways. Novel ligands can
be selected on the premise of being similar to endogenous
metabolites with the desired bioactivity profile. Pathways
for orphan metabolites could be predicted, based on their
similarity with compounds of known biological target and
mode of action. New ways to kill pathogens and to avoid
unintentionally interfering with human enzymes can be
investigated and cross-interactions between drugs and the
major human pathways can be unravelled. Last but not
least, one could predict the biological targets of bioactive
natural compounds from medicinal plants, by looking at
their similarity networks with human metabolites with
known biological targets. By adding information about
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the metabolic pathways that these metabolites are involved,
one could also extract hypotheses regarding the mode of
action and therapeutic mechanism of the medicinal plant at
the molecular level, which is at the moment the missing link
for the coupling of WM with TCM and ethnomedicine in
general.
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